The abstract is read at the publisher; the summary is JClub's.
In 99 patients with lung-only osteosarcoma recurrence after surgical resection (LOOR-FSR), median event-free survival was 4.8 months and overall survival was 26.2 months.
- Why it matters: LOOR-FSR after resection is a key setting for testing new therapies, but alternative trial endpoints and updated benchmarks are needed to interpret phase 2 single-arm results.
- What they did: The study pooled LOOR-FSR patients enrolled on three Children’s Oncology Group phase 2 single-arm trials and estimated event-free survival and overall survival, also testing demographic and baseline factors.
- The result: Twelve-month event-free survival was 22% (15–31%) across trials, with no statistically significant difference; earlier first recurrence within two years predicted higher EFS event risk (p=0.009).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.